Search
forLearn
1 / 1 resultsResearch
5 / 1000+ results
research Global Burden of Skin Disease as Reflected in Cochrane Database of Systematic Reviews
The representation of skin conditions in medical reviews partly matches their real-world impact.
research Disease Burden, Clinical Management, and Unmet Treatment Need of Patients With Moderate to Severe Alopecia Areata: Consensus Statements, Insights, and Practices From CERTAAE Delphi Panel
Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.
research Epidemiology and Burden of Alopecia Areata: A Systematic Review
Alopecia areata is a common autoimmune disease affecting about 2% of people, causing significant disability and often associated with mental health issues and other autoimmune conditions.
research Patient Prioritisation of Impact Items to Develop the Patient-Reported Impact of Dermatological Diseases (PRIDD) Measure: European Delphi Data
Patients with skin diseases rated psychological effects as most impactful, needing a treatment approach that addresses both mind and body.
research Divergent Trends in Acne Vulgaris Interest and Research: A Decade of Lost Face Value in the United States
Interest in acne is rising, but research funding has significantly decreased.
Community Join
5 / 81 resultscommunity He used Dutasteride for 20 years. Interview
community Kintor money grab, unacceptable
Kintor's KX826 (pyrilutamide) is ineffective at 0.5% and overpriced at 1%, leading to user frustration and calls for fair pricing. Users suggest sticking with proven treatments like Minoxidil and Finasteride.
community So basically we will know the efficacy of HMI-115 in 3 months after the phase II study concludes in China?
Hair loss discussion mentions HMI-115 efficacy in 3 months after Phase II study. Users discuss treatment effectiveness and mention massive regrowth in previously bald areas.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community Does pyrilutamide actually work?
Pyrilutamide, a potential hair loss treatment, and how it compares to existing treatments such as Minoxidil, Finasteride and RU58841. Real-world results are being discussed to determine its effectiveness.